Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Multiple sclerosis

Does aggressive MS warrant aggressive treatment?

Nature Reviews Neurology volume 10, pages 368–370 (2014)Cite this article

Subjects

Aggressive, refractory multiple sclerosis warrants unconventional therapy. A retrospective multicentre study assessed the effects of ablating the immune system, then reconstituting it using bone marrow derived stem cells. Though this particular regimen improved disability in some patients, others continued to relapse, perhaps indicating the treatment did not go far enough.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pfender, N., Saccardi, R. & Martin, R. Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis. Curr. Treat. Options Neurol. 15, 270–280 (2013).

    Article  PubMed  Google Scholar 

  2. Burman, J. et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J. Neurol. Neurosurg. Psychiatry http://dx.doi.org/10.1136/jnnp-2013-307207.

  3. Edan, G. et al. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J. Neurol. Neurosurg. Psychiatry 12, 1344–1350 (2011).

    Article  Google Scholar 

  4. Weiner, H. L. Immunosuppressive treatment in multiple sclerosis. J. Neurol. Sci. 223, 1–11 (2004).

    Article  CAS  PubMed  Google Scholar 

  5. Coles, A. J. et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380, 1829–1839 (2012).

    Article  CAS  PubMed  Google Scholar 

  6. Freedman, M. S. 'Time is brain' also in multiple sclerosis. Mult. Scler. 15, 1133–1134 (2009).

    Article  PubMed  Google Scholar 

  7. Scalfari, A. et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain 133, 1914–1929 (2010).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Freedman, M. S. et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can. J. Neurol. Sci. 40, 307–323 (2013).

    Article  PubMed  Google Scholar 

  9. Menon, S. et al. Characterising aggressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 84, 1192–1198 (2013).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ottawa Hospital Research Institute, University of Ottawa, 501 Smyth Road, Ottawa, K1H 5L6, ON, Canada

    Mark S. Freedman

Authors
  1. Mark S. Freedman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark S. Freedman.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Freedman, M. Does aggressive MS warrant aggressive treatment?. Nat Rev Neurol 10, 368–370 (2014). https://doi.org/10.1038/nrneurol.2014.98

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2014.98

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing